These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28159782)

  • 41. Oral activated charcoal suppresses hyperphosphataemia in haemodialysis patients.
    Wang Z; Cui M; Tang L; Li W; Wei Y; Zhu Z; Jia X; Kong X; Xu D
    Nephrology (Carlton); 2012 Sep; 17(7):616-20. PubMed ID: 22697887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study.
    Locatelli F; Dimkovic N; Pontoriero G; Spasovski G; Pljesa S; Kostic S; Manning A; Sano H; Nakajima S
    Nephrol Dial Transplant; 2010 Feb; 25(2):574-81. PubMed ID: 19736246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
    Hertel J; Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Nephron; 2015; 130(4):229-38. PubMed ID: 26184491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
    Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
    Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
    Xu J; Zhang YX; Yu XQ; Liu ZH; Wang LN; Chen JH; Fan YP; Ni ZH; Wang M; Yuan FH; Ding GH; Chen XM; Zhang AP; Mei CL
    BMC Nephrol; 2013 Feb; 14():29. PubMed ID: 23379590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
    Aramwit P; Srisawadwong R; Supasyndh O
    J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
    Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
    El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
    Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.
    Savica V; Calò LA; Monardo P; Davis PA; Granata A; Santoro D; Savica R; Musolino R; Comelli MC; Bellinghieri G
    J Am Soc Nephrol; 2009 Mar; 20(3):639-44. PubMed ID: 19020004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
    Johansson S; Rosenbaum DP; Ahlqvist M; Rollison H; Knutsson M; Stefansson B; Elebring M
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):466-475. PubMed ID: 28301096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treating hyperphosphatemia - current and advancing drugs.
    Ketteler M; Liangos O; Biggar PH
    Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.
    Akizawa T; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.
    Young DO; Cheng SC; Delmez JA; Coyne DW
    Perit Dial Int; 2009; 29(5):562-7. PubMed ID: 19776051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study.
    Sakaguchi Y; Fujii N; Shoji T; Hayashi T; Rakugi H; Iseki K; Tsubakihara Y; Isaka Y;
    PLoS One; 2014; 9(12):e116273. PubMed ID: 25545498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T; Negi S;
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.